Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Impact of age, RS and OFS on endocrine response to short preoperative ET

Oleg Gluz, MD, Evang. Krankenhaus “Bethesda” Klinik, Mönchengladbach, Germany, discusses the results of an analysis of the ADAPT and ADAPTcycle trials (NCT01779206) evaluating the impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET). Endocrine therapy response after tamoxifen or aromatase inhibitors according to RS groups was similar in both trials, but adding OFS to tamoxifen or aromatase inhibitors substantially improves endocrine therapy response in pre-patients less than or equal to 50 years, rendering similar results as in aromatase inhibitor-treated post patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.